{"id":60487,"date":"2024-02-28T06:51:06","date_gmt":"2024-02-28T06:51:06","guid":{"rendered":"https:\/\/medsname.com\/rofaday\/"},"modified":"2026-04-30T10:23:46","modified_gmt":"2026-04-30T10:23:46","slug":"rofaday","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/rofaday\/","title":{"rendered":"Rofaday"},"content":{"rendered":"<div class=\"medsbase-tldr-answer\" style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 28px 0;border-radius:4px;\">\n<h3 style=\"margin:0 0 10px 0;font-size:18px;color:#1a1a1a;\">\u26a1 R\u0103spuns rapid \u2014 Ce este Rofaday?<\/h3>\n<p><strong>Rofaday<\/strong> con\u021bine <strong>roflumilast 500 mcg<\/strong>, un <strong>inhibitor selectiv oral al fosfodiesterazei-4 (PDE4)<\/strong> luat o dat\u0103 pe zi pentru <strong>boal\u0103 pulmonar\u0103 obstructiv\u0103 cronic\u0103 sever\u0103 (BPOC) cu fenotip de bron\u0219it\u0103 cronic\u0103 \u0219i exacerb\u0103ri frecvente<\/strong>. Roflumilastul are ac\u021biune antiinflamatoare \u0219i nu bronhodilatatoare \u2014 inhib\u0103 activarea neutrofilelor \u0219i a macrofagelor \u00een c\u0103ile respiratorii, reduc\u00e2nd frecven\u021ba exacerb\u0103rilor cu ~17% \u00een studiile pivot (M2-124, M2-125, REACT). Se adaug\u0103 la tratamentul optim cu LAMA + LABA (\u00b1 ICS) la pacien\u021bii cu boal\u0103 sever\u0103. Fabricat de <strong>Cipla<\/strong>.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Ce beneficii ofer\u0103 MedsBase:<\/strong> Produc\u0103tor certificat WHO-GMP \u00b7 Ambalaj discret \u00b7 Livrare la nivel mondial \u00b7 Peste 1.400 de recenzii verificate <a href=\"https:\/\/medsbase.com\/ro\/reviews\/\">ale clien\u021bilor<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Fiecare comand\u0103 este acoperit\u0103 de politica noastr\u0103 de <a href=\"https:\/\/medsbase.com\/ro\/medsbase-re-shipment-assurance-policy\/\"><strong>Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 dac\u0103 coletul dumneavoastr\u0103 nu sose\u0219te \u00een 20 de zile lucr\u0103toare, \u00eel relivr\u0103m.<\/p>\n<h3>De ce s\u0103 comanzi de la MedsBase<\/h3>\n<p>Medicamentele noastre generice sunt procurate de la produc\u0103tori certifica\u021bi WHO-GMP \u0219i expediate la nivel mondial \u00een ambalaje discrete \u0219i simple \u2014 f\u0103r\u0103 denumirea medicamentului pe exteriorul coletului. Pl\u0103\u021bile cu cardul sunt procesate printr-un procesor reglementat (descrierile de pe extrasul de cont includ un procesor de pl\u0103\u021bi cu card reglementat \u2014 niciodat\u0103 \u201cMedsBase\u201d sau numele vreunui medicament). Accept\u0103m \u0219i criptomonede \u0219i transferuri bancare SEPA. Fiecare comand\u0103 este sus\u021binut\u0103 de Politica noastr\u0103 de Asigurare pentru Relivrare.<\/p>\n<div style=\"background:#f4f8fb;border:1px solid #e0e0e0;padding:12px 18px;margin:0 0 24px 0;border-radius:4px;font-size:14px;text-align:center;\">\n<strong>\ud83d\udd12 Checkout criptat<\/strong> \u00b7 <strong>\ud83d\udcb3 Procesator Verificat<\/strong> \u00b7 <strong>\ud83d\ude9a Livrare Worldwide<\/strong> \u00b7 <strong>\u2b50 4,9\/5 de la peste 1.400 de clien\u021bi<\/strong>\n<\/div>\n<h2>Ce este Rofaday?<\/h2>\n<p>Rofaday este un inhibitor PDE4 oral pentru BPOC sever\u0103. Roflumilast este singurul inhibitor PDE4 autorizat pentru BPOC \u2014 v\u00e2ndut interna\u021bional sub denumirile Daxas (AstraZeneca) \u0219i Daliresp. Este un tratament de ni\u0219\u0103, dar bine dovedit, adi\u021bional pentru fenotipul de bron\u0219it\u0103 cronic\u0103.<\/p>\n<h2>Cum func\u021bioneaz\u0103 Rofaday?<\/h2>\n<p>Fosfodiesteraza-4 (PDE4) este principala enzim\u0103 care degradeaz\u0103 AMP ciclic \u00een celulele inflamatorii (neutrofile, macrofage, eozinofile, celule T). Inhibarea PDE4 cre\u0219te nivelul de AMP ciclic \u00een aceste celule, suprinz\u00e2nd:<\/p>\n<ul>\n<li>Chemotaxia neutrofil\u0103 \u0219i degranularea \u00een c\u0103ile respiratorii<\/li>\n<li>Eliberarea de citokine din macrofage (TNF-\u03b1, IL-8)<\/li>\n<li>Proliferarea mu\u0219chilor netezi din c\u0103ile respiratorii \u0219i activarea fibroblastelor<\/li>\n<li>Hipersec\u021bia de mucus \u0219i hiperplazia celulelor caliciforme<\/li>\n<\/ul>\n<p>Rezultatul clinic este o reducere cu 15\u201317% a ratei de exacerbare a BPOC atunci c\u00e2nd este ad\u0103ugat la terapia inhalatorie optim\u0103.<\/p>\n<h2>Utiliz\u0103ri \u0219i indica\u021bii<\/h2>\n<ul>\n<li><strong>BPOC sever\u0103 (VEMS &lt;50% din valoarea prezis\u0103) cu bron\u0219it\u0103 cronic\u0103<\/strong> \u0219i istoric de exacerb\u0103ri, pe deasupra terapiei optime cu LAMA + LABA (\u00b1 ICS)<\/li>\n<li><strong>Fenotipul cu exacerb\u0103ri frecvente<\/strong> cu tuse productiv\u0103 persistent\u0103<\/li>\n<\/ul>\n<h2>Doza Rofaday<\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:12px 0;\">\n<thead>\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Pacient<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Doza<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Frecven\u021b\u0103<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Adul\u021bi \u2014 \u00eencepe\u021bi cu<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\"><strong>250 mcg<\/strong> primele 4 s\u0103pt\u0103m\u00e2ni<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">O dat\u0103 pe zi<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:10px;border:1px solid #ddd;\">Adul\u021bi \u2014 \u00eentre\u021binere<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\"><strong>500 mcg<\/strong><\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">O dat\u0103 pe zi, cu sau f\u0103r\u0103 m\u00e2ncare<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Insuficien\u021b\u0103 hepatic\u0103<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Evita\u021bi (Child-Pugh B\/C)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">\u2014<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>Efectele secundare ale Rofaday<\/h2>\n<ul>\n<li><strong>Pierdere \u00een greutate<\/strong> (\u00een medie 2\u20133 kg \u00een studii \u2014 monitoriza\u021bi; inversa\u021bi dac\u0103 &gt;5%)<\/li>\n<li>Diarhee, grea\u021b\u0103 (motivul cel mai frecvent de \u00eentrerupere; de obicei se ameliorizeaz\u0103 dup\u0103 primele 2\u20134 s\u0103pt\u0103m\u00e2ni)<\/li>\n<li>Dureri de cap<\/li>\n<li>Insomnie, anxietate<\/li>\n<li>Dispepsie, durere abdominal\u0103<\/li>\n<li>Modific\u0103ri ale st\u0103rii de spirit \u2014 depresie, anxietate; rareori idei suicidare (avertisment)<\/li>\n<\/ul>\n<p><strong>Severe \u2014 \u00eentrerupe\u021bi \u0219i c\u0103uta\u021bi ajutor medical:<\/strong><\/p>\n<ul>\n<li>Pierdere semnificativ\u0103 \u00een greutate (&gt;5% din greutatea corporal\u0103)<\/li>\n<li>Depresie nou\u0103 sau agravat\u0103, g\u00e2nduri suicidare<\/li>\n<li>Diarree persistent\u0103 sever\u0103<\/li>\n<li>Reac\u021bie alergic\u0103 sever\u0103<\/li>\n<\/ul>\n<h2>Avertismente \u0219i precau\u021bii<\/h2>\n<ul>\n<li><strong>Stare de spirit \u0219i comportament:<\/strong> testa\u021bi pentru depresie \u00eenainte de \u00eenceperea tratamentului; avertiza\u021bi pacien\u021bii\/familiile s\u0103 raporteze orice simptom nou legat de stare de spirit.<\/li>\n<li><strong>Pierdere \u00een greutate:<\/strong> monitorizarea greut\u0103\u021bii la baz\u0103 \u0219i la fiecare 3 luni; dac\u0103 pierderea dep\u0103\u0219e\u0219te 5%, reevalua\u021bi sau \u00eentrerupe\u021bi tratamentul.<\/li>\n<li><strong>Afectare hepatic\u0103:<\/strong> evita\u021bi la pacien\u021bii Child-Pugh B \u0219i C.<\/li>\n<li><strong>titrare doz\u0103 pe 4 s\u0103pt\u0103m\u00e2ni<\/strong> (250 mcg) reduce efectele secundare gastrointestinale \u0219i diareea \u2014 majoritatea pacien\u021bilor pot tolera apoi 500 mcg.<\/li>\n<li><strong>Nu este un bronhodilatator<\/strong> \u2014 nu \u00eenlocuie\u0219te LAMA, LABA sau ICS.<\/li>\n<li><strong>Sarcin\u0103 \u0219i al\u0103ptare:<\/strong> contraindicated.<\/li>\n<li><strong>Interac\u021biuni medicamentoase:<\/strong> Inductorii CYP3A4 (rifampicin\u0103) reduc nivelurile \u2014 evita\u021bi. Inhibitorii puternici ai CYP1A2 (fluvoxamin\u0103, ciprofloxacin\u0103) cresc nivelurile \u2014 ave\u021bi precau\u021bie.<\/li>\n<\/ul>\n<h2>Contraindica\u021bii<\/h2>\n<ul>\n<li>Hipersensibilitate la roflumilast<\/li>\n<li>Disfunc\u021bie hepatic\u0103 moderat-p\u00e2n\u0103 la sever\u0103 (Child-Pugh B\/C)<\/li>\n<li>Sarcin\u0103<\/li>\n<\/ul>\n<h2>Interac\u021biuni medicamentoase<\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:12px 0;\">\n<thead>\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Medicament interactiv<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Efect<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Ce s\u0103 face\u021bi<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Inductori CYP3A4 (rifampicin\u0103, fenobarbital, fenitoin\u0103, carbamazepin\u0103)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Reduc nivelurile de roflumilast cu 50%<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Evita\u021bi<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:10px;border:1px solid #ddd;\">Inhibitori puternici ai CYP1A2 (fluvoxamin\u0103, ciprofloxacin\u0103, enoxacin\u0103)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Cre\u0219te nivelurile de roflumilast \u2014 cre\u0219te riscul de efecte adverse<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Precau\u021bie; lua\u021bi \u00een considerare o doz\u0103 mai mic\u0103<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Contraceptive orale care con\u021bin gestoden<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Cre\u0219tere modest\u0103 a nivelurilor de roflumilast<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">De obicei, nu este necesar\u0103 ajustarea dozei<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>Depozitare<\/h2>\n<ul>\n<li>Depozita\u021bi la temperaturi sub <strong>25\u00b0C<\/strong> \u00eentr-un loc r\u0103coros \u0219i uscat, departe de lumina direct\u0103 a soarelui.<\/li>\n<li>P\u0103stra\u021bi \u00een ambalajul original p\u00e2n\u0103 la utilizare pentru a proteja de umiditate \u0219i lumin\u0103.<\/li>\n<li>Nu utiliza\u021bi dup\u0103 data de expirare tip\u0103rit\u0103 pe blister.<\/li>\n<li>P\u0103stra\u021bi la distan\u021b\u0103 de copii.<\/li>\n<\/ul>\n<h2>Alternative conexe pe MedsBase<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/asthalin-inhaler\/\"><strong>Asthalin Inhaler \u2014 salbutamol pentru ameliorarea simptomelor<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/budecort-inhaler\/\"><strong>Budecort Inhaler \u2014 budesonide ICS pentru preven\u021bie<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/foracort-inhaler\/\"><strong>Inhalator Foracort \u2014 budesonid\u0103 + formoterol ICS-LABA<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/tiova-inhaler\/\"><strong>Tiova Inhaler \u2014 tiotropium LAMA pentru BPOC<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/montair\/\"><strong>Montair \u2014 comprimat montelukast LTRA<\/strong><\/a><\/li>\n<\/ul>\n<h2 id=\"faqs\">\u00centreb\u0103ri frecvente<\/h2>\n<h3>C\u00e2nd se adaug\u0103 Rofaday?<\/h3>\n<p>Pentru BPOC sever (FEV1 &lt;50% din valoarea prezis\u0103) cu fenotip de bron\u0219it\u0103 cronic\u0103 \u0219i istoric de exacerb\u0103ri frecvente pe deasupra terapiei optime cu LAMA + LABA (\u00b1 ICS). Nu este indicat pentru BPOC u\u0219oar\u0103 sau astm.<\/p>\n<h3>De ce trebuie s\u0103 \u00eencep cu 250 mcg?<\/h3>\n<p>O titrare de 4 s\u0103pt\u0103m\u00e2ni la 250 mcg reduce dramatic efectele adverse gastrointestinale (diaree, grea\u021b\u0103) \u2014 majoritatea pacien\u021bilor pot apoi trece la doza de \u00eentre\u021binere de 500 mcg f\u0103r\u0103 intoleran\u021b\u0103.<\/p>\n<h3>Cu c\u00e2t reduce Rofaday exacerb\u0103rile?<\/h3>\n<p>Aproximativ 15\u201317% reducere a exacerb\u0103rilor moderate-grele de BPOC \u00een studiile pivot (M2-124, M2-125, REACT). Cel mai mare beneficiu s-a observat la fenotipul de bron\u0219it\u0103 cronic\u0103 cu exacerb\u0103ri frecvente.<\/p>\n<h3>Rofaday m\u0103 va face s\u0103 sl\u0103besc?<\/h3>\n<p>Da \u2014 \u00een medie 2\u20133 kg \u00een studii. Monitoriza\u021bi greutatea la ini\u021biere \u0219i la fiecare 3 luni. Dac\u0103 pierderea dep\u0103\u0219e\u0219te 5%, reevalua\u021bi indica\u021bia sau \u00eentrerupe\u021bi tratamentul.<\/p>\n<h3>Dar modific\u0103rile de stare de spirit?<\/h3>\n<p>Rar dar raportat. Efectua\u021bi screening pentru depresie la ini\u021biere; consilia\u021bi pacientul \u0219i familia s\u0103 raporteze orice simptom nou de dispozi\u021bie, anxietate sau g\u00e2nduri suicidare. \u00centrerupe\u021bi \u0219i reevalua\u021bi.<\/p>\n<h3>Rofaday este un bronhodilatator?<\/h3>\n<p>Nu \u2014 are doar efect antiinflamator. Continua\u021bi inhalatoarele de LAMA, LABA \u0219i (unde indicat) ICS.<\/p>\n<h3>Pot lua Rofaday \u00een timpul sarcinii?<\/h3>\n<p>Contraindicated.<\/p>\n<h3>Cum se compar\u0103 Rofaday cu terapia tripl\u0103?<\/h3>\n<p>Inhalatorul triplu (Triohale) \u0219i Rofaday abordeaz\u0103 exacerb\u0103rile de BPOC prin mecanisme diferite (bronhodilata\u021bie + suprima\u021bie inflama\u021biei vs antiinflama\u021bie mediat\u0103 de PDE4). Unii pacien\u021bi beneficiaz\u0103 de ambele.<\/p>\n<h3>Care sunt cele mai importante interac\u021biuni medicamentoase?<\/h3>\n<p>Rifampicina (\u0219i al\u021bi inductori ai CYP3A4) reduc nivelurile de Rofaday la jum\u0103tate \u2014 evita\u021bi. Inhibitorii puternici ai CYP1A2 (fluvoxamina, ciprofloxacina) cresc nivelurile \u2014 ave\u021bi grij\u0103.<\/p>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:14px 18px;margin:24px 0;border-radius:4px;font-size:13px;\"><strong>Avertizare medical\u0103:<\/strong> Aceast\u0103 pagin\u0103 are scop informativ \u0219i nu \u00eenlocuie\u0219te sfatul medical profesionist. Consult\u0103 \u00eentotdeauna un profesionist calificat \u00een s\u0103n\u0103tate \u00eenainte de a \u00eencepe, \u00eentrerupe sau schimba orice inhalator sau medicament respirator, mai ales dac\u0103 ai alte afec\u021biuni medicale, iei alte re\u021bete, e\u0219ti gravid\u0103 sau al\u0103ptezi, sau ai peste 65 de ani.<\/div>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Alternative conexe<\/h3>\n<p>Alte produse din <strong>Afec\u021biuni cronice<\/strong> pe care clien\u021bii le vizualizeaz\u0103 de asemenea:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/glycomet-gp\/\">Glycomet-GP<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/loratin\/\">Loratin<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/lasix\/\">Lasix<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/decdan\/\">Decdan<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/hydrocl\/\">Hydrocl<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Reduce inflama\u021bia pulmonar\u0103<br \/>\n\u2705 \u00cembun\u0103t\u0103\u021be\u0219te func\u021bia pulmonar\u0103<br \/>\n\u2705 Trateaz\u0103 bron\u0219ita cronic\u0103<br \/>\n\u2705 Reduce exacerb\u0103rile la BPOC<br \/>\n\u2705 \u00cembun\u0103t\u0103\u021be\u0219te capacitatea de respira\u021bie<\/p>\n<p>Rofaday con\u021bine Roflumilast.<\/p>","protected":false},"featured_media":60488,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3681,3141,3223],"product_tag":[4868,4869],"class_list":{"0":"post-60487","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-asthma-copd-treatment","7":"product_cat-category-overview","8":"product_cat-chronic-conditions","9":"product_tag-rofaday","10":"product_tag-roflumilast","12":"first","13":"instock","14":"shipping-taxable","15":"purchasable","16":"product-type-variable","17":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product\/60487","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/comments?post=60487"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media\/60488"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media?parent=60487"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_brand?post=60487"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat?post=60487"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_tag?post=60487"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}